Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network
- PMID: 22385937
- PMCID: PMC3503538
- DOI: 10.1016/j.cardfail.2011.12.009
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network
Abstract
Background: Worsening renal function is common among patients hospitalized for acute decompensated heart failure (ADHF). When this occurs, subsequent management decisions often pit the desire for effective decongestion against concerns about further worsening renal function. There are no evidence-based treatments or guidelines to assist in these difficult management decisions. Ultrafiltration is a potentially attractive alternative to loop diuretics for the management of fluid overload in patients with ADHF and worsening renal function.
Methods and results: The National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network designed a clinical trial to determine if ultrafiltration results in improved renal function and relief of congestion compared with stepped pharmacologic care when assessed 96 hours after randomization in patients with ADHF and cardiorenal syndrome. Enrollment began in June 2008. This paper describes the rationale and design of the Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF).
Conclusions: Treating the signs and symptoms of congestion in ADHF is often complicated by worsening renal function. CARRESS-HF compares treatment strategies (ultrafiltration vs stepped pharmacologic care) for the management of worsening renal function in patients with ADHF. The results of the CARRESS-HF trial are expected to provide information and evidence as to the most appropriate approaches for treating this challenging patient population.
Copyright © 2012 Elsevier Inc. All rights reserved.
Figures

Similar articles
-
Is there still a role for ultrafiltration in the management of acute heart failure? CARRESS and beyond.Curr Heart Fail Rep. 2013 Sep;10(3):185-9. doi: 10.1007/s11897-013-0142-z. Curr Heart Fail Rep. 2013. PMID: 23728784 Review.
-
Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure.JACC Heart Fail. 2015 Feb;3(2):97-107. doi: 10.1016/j.jchf.2014.09.003. Epub 2014 Oct 31. JACC Heart Fail. 2015. PMID: 25543972 Free PMC article. Clinical Trial.
-
Ultrafiltration for the treatment of congestion: a window into the lung for a better caress to the heart.Nephrol Dial Transplant. 2014 Jul;29(7):1335-41. doi: 10.1093/ndt/gft371. Epub 2013 Sep 5. Nephrol Dial Transplant. 2014. PMID: 24009283 Review.
-
Cardiorenal syndrome and the role of ultrafiltration in heart failure.Curr Heart Fail Rep. 2013 Mar;10(1):81-8. doi: 10.1007/s11897-012-0129-1. Curr Heart Fail Rep. 2013. PMID: 23354831 Review.
-
Ultrafiltration in decompensated heart failure with cardiorenal syndrome.N Engl J Med. 2012 Dec 13;367(24):2296-304. doi: 10.1056/NEJMoa1210357. Epub 2012 Nov 6. N Engl J Med. 2012. PMID: 23131078 Free PMC article. Clinical Trial.
Cited by
-
Cardiorenal [corrected] syndrome: an emerging problem in pediatric critical care.Pediatr Nephrol. 2013 Jun;28(6):855-62. doi: 10.1007/s00467-012-2251-4. Epub 2012 Jul 18. Pediatr Nephrol. 2013. PMID: 23010840 Review.
-
Contemporary strategies in the diagnosis and management of heart failure.Mayo Clin Proc. 2014 May;89(5):662-76. doi: 10.1016/j.mayocp.2014.01.004. Epub 2014 Mar 29. Mayo Clin Proc. 2014. PMID: 24684781 Free PMC article. Review.
-
Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research.J Am Coll Cardiol. 2017 May 16;69(19):2428-2445. doi: 10.1016/j.jacc.2017.03.528. J Am Coll Cardiol. 2017. PMID: 28494980 Free PMC article. Review.
-
High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network.J Am Heart Assoc. 2018 Dec 18;7(24):e010364. doi: 10.1161/JAHA.118.010364. J Am Heart Assoc. 2018. PMID: 30561266 Free PMC article.
-
SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules.Front Nephrol. 2023 Jan 12;2:1109321. doi: 10.3389/fneph.2022.1109321. eCollection 2022. Front Nephrol. 2023. PMID: 37674989 Free PMC article. Review.
References
-
- Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39. - PubMed
-
- Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331–8. - PubMed
-
- Forman DE, Butler J, Wang Y, Abraham WT, O'connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–7. - PubMed
-
- Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail. 2006;12:257–62. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous